Last reviewed · How we verify
Diclofenac Test (upper dose)
Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and decrease inflammation and pain.
Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and decrease inflammation and pain. Used for Acute pain management (Phase 3 trial indication for upper dose formulation), Chronic inflammatory conditions such as osteoarthritis or rheumatoid arthritis.
At a glance
| Generic name | Diclofenac Test (upper dose) |
|---|---|
| Sponsor | Iroko Pharmaceuticals, LLC |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID) |
| Target | COX-1 and COX-2 |
| Modality | Small molecule |
| Therapeutic area | Pain Management / Rheumatology |
| Phase | Phase 3 |
Mechanism of action
Diclofenac blocks both COX-1 and COX-2 enzymes, which are responsible for producing prostaglandins that mediate inflammation, pain, and fever. By reducing prostaglandin levels, diclofenac provides analgesic and anti-inflammatory effects. The 'upper dose' designation in this Phase 3 trial likely refers to evaluation of a higher dosing regimen compared to standard formulations.
Approved indications
- Acute pain management (Phase 3 trial indication for upper dose formulation)
- Chronic inflammatory conditions such as osteoarthritis or rheumatoid arthritis
Common side effects
- Gastrointestinal upset (nausea, dyspepsia, abdominal pain)
- Headache
- Dizziness
- Increased cardiovascular risk (with chronic use)
- Renal impairment (with chronic use)
Key clinical trials
- Study of Diclofenac Capsules to Treat Pain Following Bunionectomy (PHASE3)
- Study of Diclofenac Capsules to Treat Dental Pain (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Diclofenac Test (upper dose) CI brief — competitive landscape report
- Diclofenac Test (upper dose) updates RSS · CI watch RSS
- Iroko Pharmaceuticals, LLC portfolio CI